Bacteria-Based Biosensor Detects Zinc Deficiency
|
By LabMedica International staff writers Posted on 14 Sep 2015 |

Image: Plate containing E. coli producing a purple pigment indicative of low levels of zinc. The bacterium could be used to detect nutritional deficiencies in resource-limited areas of the world (Photo courtesy of Rob Felt, Georgia Institute of Technology).
A series of genetic engineering steps led to the development of a bacterial biosensor capable of visually distinguishing levels of zinc, a critical micronutrient.
Micronutrient deficiencies, including zinc deficiency, are responsible for hundreds of thousands of deaths annually. A key obstacle to allocating scarce treatment resources is the ability to measure population blood micronutrient status inexpensively and quickly enough to identify those who most need treatment.
To overcome this obstacle a team of molecular microbiologists at the Georgia Institute of Technology (Atlanta, USA) developed a novel approach for inexpensive screening of micronutrients, with zinc being the test case.
Towards this end, the investigators genetically engineered a strain of Escherichia coli to produce different colored pigments (violacein, lycopene, and beta-carotene) in response to different extracellular zinc levels. Genes for the pigments were taken from other organisms and inserted into the E. coli on a plasmid. The red and orange colors, lycopene and beta-carotene, were produced by genes taken from Pantoea anantis, a plant pathogen. The purple color, violacein, came from a soil bacterium.
Obtaining discrete color states in the carotenoid pathway required precise engineering of the E. coli's metabolism to prevent a reaction at low zinc concentrations but allow complete reaction at higher concentrations, and all under the constraints of the bacterium's natural regulator limitations. A combination of gene dosage, post-transcriptional, and post-translational regulation was necessary to allow visible color change over physiologically relevant ranges representing a small fraction of the regulator’s dynamic response range, with further tuning possible by modulation of precursor availability.
In practice, a pellet of the engineered bacteria was mixed with the plasma from a human subject. The E. coli multiplied, producing the color corresponding to the level of zinc in the sample. Purple corresponded to dangerously low levels, while red indicated borderline levels, and orange normal levels. The color was readily visible without any diagnostic or other electronic equipment.
"We think this is just enough technology to meet the needs," said Dr. Mark Styczynski, assistant professor of chemical and bio-molecular engineering at the Georgia Institute of Technology. "Information we can provide could one day help nutritional epidemiologists and non-governmental organizations determine the populations of people that may need interventions to address nutritional deficiencies."
"The general idea of bio-sensing is certainly out there, but we have taken the step of developing a system that does not require equipment in the field," said Dr. Styczynski. "We believe this will work well in low-resource areas. This is a convincing proof-of-principle, and we hope to begin the translational aspects of this system based on what we have already shown. It is a matter now of reducing this to practice for something that will ultimately be useful."
The novel assay for zinc deficiency was described in a paper published in the September 2015 issue of the journal Metabolic Engineering.
Related Links:
Georgia Institute of Technology
Micronutrient deficiencies, including zinc deficiency, are responsible for hundreds of thousands of deaths annually. A key obstacle to allocating scarce treatment resources is the ability to measure population blood micronutrient status inexpensively and quickly enough to identify those who most need treatment.
To overcome this obstacle a team of molecular microbiologists at the Georgia Institute of Technology (Atlanta, USA) developed a novel approach for inexpensive screening of micronutrients, with zinc being the test case.
Towards this end, the investigators genetically engineered a strain of Escherichia coli to produce different colored pigments (violacein, lycopene, and beta-carotene) in response to different extracellular zinc levels. Genes for the pigments were taken from other organisms and inserted into the E. coli on a plasmid. The red and orange colors, lycopene and beta-carotene, were produced by genes taken from Pantoea anantis, a plant pathogen. The purple color, violacein, came from a soil bacterium.
Obtaining discrete color states in the carotenoid pathway required precise engineering of the E. coli's metabolism to prevent a reaction at low zinc concentrations but allow complete reaction at higher concentrations, and all under the constraints of the bacterium's natural regulator limitations. A combination of gene dosage, post-transcriptional, and post-translational regulation was necessary to allow visible color change over physiologically relevant ranges representing a small fraction of the regulator’s dynamic response range, with further tuning possible by modulation of precursor availability.
In practice, a pellet of the engineered bacteria was mixed with the plasma from a human subject. The E. coli multiplied, producing the color corresponding to the level of zinc in the sample. Purple corresponded to dangerously low levels, while red indicated borderline levels, and orange normal levels. The color was readily visible without any diagnostic or other electronic equipment.
"We think this is just enough technology to meet the needs," said Dr. Mark Styczynski, assistant professor of chemical and bio-molecular engineering at the Georgia Institute of Technology. "Information we can provide could one day help nutritional epidemiologists and non-governmental organizations determine the populations of people that may need interventions to address nutritional deficiencies."
"The general idea of bio-sensing is certainly out there, but we have taken the step of developing a system that does not require equipment in the field," said Dr. Styczynski. "We believe this will work well in low-resource areas. This is a convincing proof-of-principle, and we hope to begin the translational aspects of this system based on what we have already shown. It is a matter now of reducing this to practice for something that will ultimately be useful."
The novel assay for zinc deficiency was described in a paper published in the September 2015 issue of the journal Metabolic Engineering.
Related Links:
Georgia Institute of Technology
Latest BioResearch News
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
Channels
Clinical Chemistry
view channel
Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read more
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read moreMolecular Diagnostics
view channel
Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
Assessing early benefit from immunotherapy in advanced non-small cell lung cancer can be challenging because radiographic responses may take months to become clear. Early scans can also be difficult to... Read more
Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
Recurrent hepatocellular carcinoma (HCC) after surgery remains a major cause of poor outcomes and contributes to liver cancer’s rank as the world’s third leading cause of cancer death. The burden is particularly... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channelProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







